

Clinical efficacy of a next-generation sequencing gene panel for primary immunodeficiency diagnostics

William Rae^{1,2*}, Daniel Ward³, Christopher Mattocks³, Reuben J. Pengelly⁴, Efrem Eren¹, Sanjay V. Patel⁵, Saul N. Faust^{2,4,5}, David Hunt⁶, Anthony P. Williams^{1,3,4}

Affiliations:

¹Department of Immunology, University Hospital Southampton NHSFT, Southampton, UK.

²Southampton National Institute for Health Research Clinical Research Facility, University Hospital Southampton NHSFT, Southampton, UK.

³Wessex Investigational Sciences Hub Laboratory, University Hospital Southampton NHSFT, Southampton, UK.

⁴Faculty of Medicine, University of Southampton, Southampton, UK.

⁵Paediatric Immunology and Infectious Disease, Children's Hospital Southampton, Southampton, UK.

⁶Wessex Clinical Genetics Service, University Hospital Southampton NHSFT, Southampton, UK.

*Corresponding Author

Dr William Rae

Southampton NIHR Wellcome Trust Clinical Research Facility

Mail Point 218, C Level,

University Hospital Southampton NHSFT,

Tremona Road,

Southampton, UK

Email: will.rae@nhs.net

Tele: +44 7919075724

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cge.13163

Conflicts of interest: The authors have no conflicts of interest to declare

Acknowledgements

We thank the patients and their families for participating in this study. This work was supported by the Wessex Investigational Sciences Hub at the University of Southampton.

ABSTRACT

Primary immunodeficiencies (PIDs) are rare monogenic inborn errors of immunity that result in impairment of functions of the human immune system. PIDs have a broad phenotype with increased morbidity and mortality and treatment choices are often complex. With increased accessibility of next-generation sequencing the rate of discovery of genetic causes for PID has increased exponentially. Identification of an underlying monogenic diagnosis provides important clinical benefits for patients with the potential to alter treatments, facilitate genetic counselling, and pre-implantation diagnostics. We investigated a next-generation sequencing PID panel of 242 genes within clinical care across a range of PID phenotypes. We also evaluated *Phenomizer* to predict causal genes from human phenotype ontology (HPO) terms. 27 participants were recruited and a total of 15 reportable variants were identified in 48% (13/27) of the participants. The panel results had implications for treatment in 37% (10/27) of participants. *Phenomizer* identified the genes harbouring variants from HPO terms in 33% (9/27) of participants. This study demonstrates the clinical efficacy that genetic testing has in the care of PID. However, it also highlights some of the disadvantages of gene panels in the rapidly moving field of PID genomics and current challenges in HPO term assignment for PID.

KEY WORDS

Primary immunodeficiency, next-generation sequencing, clinical diagnostics, human phenotype ontology.

INTRODUCTION

Primary immunodeficiency (PIDs) are inborn errors of immunity that encompass a collection of rare monogenic diseases resulting in impairment of one or more functions of the human immune system. PID has a broad phenotype including; severe susceptibility to infections, allergy, autoimmunity/inflammation, and malignancy. [1] These disease manifestations cause increased morbidity and mortality in patients and treatment choices are often complex. With the increased accessibility of next-generation sequencing (NGS) the rate of discovery of genetic causes for PID has increased exponentially in recent years, with now over 300 monogenic causes for PID described. [2, 3]

The increasing number of monogenic causes identified for PID, coupled with knowledge of how these genetic alterations impact on protein and cellular functions, has led to the introduction of precision medical interventions targeting specific defects in patients. [4, 5] Traditional treatments for PID consist of prophylaxis against infection, with antimicrobials and immunoglobulin, iatrogenic immunomodulation with high inherent risk associated with additional untargeted immunosuppression, and bone marrow transplantation in severe cases. Precision therapies now include targeted immunosuppression in cases of autoimmune/inflammatory manifestations and gene therapy to correct germline errors in autologous haematopoietic stem cells. [6, 7] These therapeutic approaches have the potential to dramatically improve the prognoses for patients with PID. [7-9] Precision treatments, as well with genetic family counselling and pre-implantation diagnostics, are only possible with knowledge of the causal monogenic variant in patients, and recent progressions in diagnostics and treatments underline the importance of genomic investigations in the clinical care of patients with PID. [10, 11]

Current genomic methodologies used for the investigation vary from Sanger sequencing of single candidate genes, to NGS gene panels, whole exome sequencing (WES) and now whole genome sequencing (WGS). [12-14] The most widely used technique within routine clinical care remains NGS gene panels due to economic, data handling, and result turnaround time advantages. [15] NGS gene panels can provide a comprehensive method for diagnostics in PID, with reported diagnostic rates between 15%-70%, depending on the PID population and phenotypic criteria of patients assessed. [16-19]

Due to the importance that a genetic diagnosis can have in the clinical management of PID, we investigated the diagnostic utility of an NGS panel of 242 PID genes in clinical practice. To reflect patients encountered within routine clinics, we recruited and collected phenotypic data from a heterogeneous range of PID participants using Human Phenotype Ontology (HPO) terms. [1, 20] We also assessed the ability of *Phenomizer* to construct candidate gene lists from participant HPO terms. [21]

MATERIALS AND METHODS

Participants

27 genetically undiagnosed participants with a phenotype compatible with PID, [1] and a diagnosis of PID according to the European Society for Immunodeficiencies ([ESID](https://esid.org/Working-Parties/Registry/Diagnosis-criteria)) (<https://esid.org/Working-Parties/Registry/Diagnosis-criteria>) were enrolled from a single centre. Written informed consent was obtained from all participants (REC reference 12/NW/0794, ERGO 21562).

Study Design

This study was a prospective cohort study. Inclusion criteria were; a clinical diagnosis of PID, attendance at a Primary Immunodeficiency Clinic (Adult or Paediatric) at University Hospital Southampton NHSFT, and the ability of the participant or parent/guardian to provide written informed consent. Exclusion criteria were; prior knowledge of the genetic cause of PID, and/or previous bone marrow transplant or gene therapy. A target cohort size of 20-30 participants was chosen based on results of previously published studies. [19, 22]

Clinical phenotyping

Clinical phenotyping was performed from analysis of patient medical records and laboratory results. Phenotypic data was recorded in HPO terms (**S1 Table**).

DNA preparation

5mls of EDTA blood was taken from participants. DNA was extracted using DNeasy Blood and Tissue Kit (Qiagen, Hilden, DE) according to the manufacturer's instructions. DNA quality was checked by Nanodrop spectrophotometry (ThermoFisher, MA, USA). DNA quality requirements were a 260/280 ratio of 1.70 -1.90 and a minimum DNA concentration of 20ng/ul.

Library preparation and sequencing

DNA libraries were prepared using a Nextera® Rapid Capture Enrichment protocol according to the manufacturer's instructions (TruSight™ One Sequencing Panel, FC-141-1007, Illumina, USA, CA). Briefly, individual genomic DNA samples were fluorometrically quantified and 50ng of DNA was enzymatically fragmented and tagged. Resulting genomic libraries were then dual indexed and amplified by polymerase chain reaction (PCR) using

sample specific index primer pairs. 500ng of each indexed library was pooled on a 12 samples per protocol basis. The prepared pools were subjected to 2 rounds of library enrichment, biotinylated capture probes were hybridized to the DNA, captured with streptavidin coated magnetic beads, stringency washed and eluted to produce the enriched DNA library. The enriched DNA library was then further amplified by PCR. Three amplified enriched libraries were equimolar pooled to produce a final library for sequencing containing 36 individual samples. Sample purification steps were performed throughout the procedure as recommended. Prepared libraries were denatured and diluted to 1.8pMol as per the manufacturer's instructions (15048776, Illumina Ca, USA). 2x 151bp paired end sequencing was performed using a NextSeq® 500 High Output v2 Kit (FC-404-2004, Illumina, CA, USA) on a NextSeq 500 sequencing system (SY-415-1001, Illumina, CA, USA) according to the manufacturer's instructions.

Bioinformatic analysis

Per-cycle BCL basecall files were converted to demultiplexed per-read FASTQ files using bcl2fastq software (Illumina, CA, USA). Resulting FASTQ files were quality checked and processed according to GATK best practice guidelines and aligned to the GRCh37/hg19 reference genome using BWA-MEM. Variants were called from the Binary Alignment Map (BAM) file using GATK: unified genotype caller. BAM and Variant Call Format (VCF) files were then uploaded and annotated by the online module Sapientia (Congenica, Cambridge, UK) for filtering and analysis of variants.

Variant filtering

Data from the TruSight One (Illumina, CA, USA) 4813 gene exon panel was filtered to include only the virtual PID gene panel of 242 genes (**S2 Table**). Variants were then filtered to only include; missense, frameshift, nonsense, and canonical splice site variants, single nucleotide polymorphisms (SNPs) and indels. Remaining variants were then filtered to a minor allele frequency (MAF) of <0.01 in the Exome Aggregation Consortium (ExAC). [23] Variants were then interrogated using *in silico* predictive tools PolyPhen2, [24], SIFT, [25] and Ensembl variant effector predictor (VEP). [26] BAM file read alignments were visually inspected for each variant identified using Integrative Genomics Viewer (IGV). [27] Variants were subsequently graded according to the American College of Medical Genetics (ACMG) criteria. [28, 29] Reportable variants were defined as those classed by ACMG criteria as

pathogenic, likely pathogenic, or variants with clinical implications for PID disease management through clinical risk modification in PID.

To investigate whether the finding of ≥ 2 reportable variants in any single individual presented distinct blended phenotypes or potential digenic/multigenic inheritance as the basis for disease, GeneMANIA was used to assess for interactions and expression of genes and proteins within cellular pathways. [30, 31]

***Phenomizer* candidate gene lists filtering**

HPO terms for each participant were input into *Phenomizer* (<http://compbio.charite.de/phenomizer/>) to generate gene lists. Candidate gene lists were then compiled for each individual (**S4 Table**) using a cut-off of $p < 0.05$ for gene likelihood probabilities as calculated by Monte Carlo random sampling with Bonferroni correction (a method known as Ontology Similarity Search with p values). [21]

RESULTS

Clinical phenotypes

All 27 participants had a range of phenotypes compatible with PID. [1] The number of HPO terms assigned to participants ranged from minimum of 2 to maximum of 13 (median = 6) (**Fig 1 and S1 Table**).

242 PID gene panel results

There was coverage of >1x read depth in 99.52%, >30x read depth in 96.19%, and >50x read depth in 87.57% of the targeted exonic sequence across the 242 genes in the PID virtual panel (**S2 Table**). The mean read depth over the reportable variants was 98 reads (**Table 1**). 67 known PID genes are not covered by TruSight One Sequencing Panel and not included in the 242 PID gene panel (**S3 Table**).

46% (13/27) of individuals investigated by the NGS PID gene panel had a monogenic diagnosis identified. 15 reportable variants were identified that were either graded as pathogenic/likely pathogenic and/or had clinical implications in the 13 participants. A variant in *TNFRSF13B*, despite previously being reported as pathogenic, was only determined as a variant of unknown significance according to ACMG criteria (**Table 1**). Novel variants were found in *NFKB1*, *IKBKG*, *GATA2*, *TAZ*, *PIK3CD* and *CTLA4*. Variants previously reported as pathogenic were identified in *PIK3CD*, [32] *IFNGR1*, [33] *STXBP2*, [34] *STAT1*, [35] *NLRP3*, [36] and *TNFRSF13B*. [37]

73% (11/15) of reportable variants were loss-of-function (LOF) and 28% (4/15) variants were gain-of-function (GOF). Variants were graded according to ACMG criteria with 47% (7/15) of identified variants being classified as pathogenic, 47% (7/15) classified as likely pathogenic, and 6% (1/15) a variant of undetermined significance (VUS), but in the clinical context considered reportable due to disease risk modification (**Table 1**).

P1 underwent an array comparative genomic hybridisation (aCGH) which identified a large 2Mb monoallelic deletion within the 6q15 region (90511889-92156885). This deletion contained the genes *MDN1*, *BACH2*, *MAP3K7*, *CASP8AP2*, and *GJA10*. Haploinsufficiency of the transcription factor *BACH2* has recently been described to cause immunodeficiency with autoimmunity, which is a similar clinical phenotype to that of P1, making this the likely cause of the participant's PID. [39]

Two participants (P7 and P26) had 2 reportable variants identified. We assessed whether these two gene variants were likely to contribute to a blended phenotype of two distinct phenotypes that overlap within the individuals, or potentially contributed in a digenic mechanism for disease. Using GeneMANIA, we mapped the physical interactions of protein products, biological pathways, and genetic interactions of the genes *GATA2:NLRP3* and *STAT1:TNFRSF13B* which did not find evidence of interactions (**Fig 2**).

***Phenomizer* candidate gene list results**

Phenomizer derived candidate gene lists identified the genes with reportable variants in 33% (9/27) of participants found to have a monogenic diagnosis (P2, P3, P5, P7, P16, P17, P23, P26, P27). *Phenomizer* did not identify the gene containing the reportable variant in 37% (4/13) of participants (P10, P20, P24, P25). Candidate gene lists could not be generated for P9 and P11 due to none of the predicted genes returned by *Phenomizer* having a significance level of $p < 0.05$.

In those participants who remained undiagnosed (P1, P4, P6, P8, P9, P11, P12, P13, P14, P15, P18, P19, P21, P22), filtering of variants from the *Phenomizer* candidate gene lists did not identify any reportable variants (**S4 Table**).

Clinical management and treatment implications

The genetic information gained from the 242 PID gene panel had implications for clinical management and treatment in 37% 10/27 of the cohort (**Table 2**).

NFKB1 haploinsufficiency is described to cause a wide range of autoimmune/inflammatory diseases. [40, 41] Both P2 and P3 presented with autoimmune cytopenias and although both currently in remission, knowledge of the underlying genetic cause has meant that their immunosuppression with mycophenolate mofetil (MMF) should not be withdrawn due to high risk of disease relapse. Patients with *NFKB1* haploinsufficiency suffer with EBV reactivation and disease due to intrinsic NK cell defects. [42] From the clinical and immunological phenotypes of P2 and P3 we would not have expected this, but now with knowledge of the monogenic PID cause we will continually monitor EBV viral loads due to lymphoma risk. [43]

In P16 and P20, pathogenic *CTLA4* missense variants cause immunodeficiency with multi-system autoimmunity due to impaired regulatory T cell function. [44, 45] A precision therapy

can be administered in these patients with CTLA4:Ig fusion protein (Abatacept) to target autoimmunity. [44, 46]

Activated phosphoinositide 3-kinase delta syndrome (APDS) due to GOF variants in *PIK3CD* can cause lymphoproliferation and autoimmunity disease which is a significant cause of increased mortality. [47] These disease manifestations respond to inhibition of the hyperfunctional PIK3 δ -AKT-mTOR pathway in lymphocytes of patients with use of mTOR inhibition by sirolimus, or with PIK3 δ inhibitors such as idelalisib. [48, 49]

Heterozygous frameshift variants in *IFNGR1* cause recurrent infection with low virulence non-tuberculous mycobacteria (NTM) due to expression of a non-functional cell surface receptor on patients' cells that acts as a 'decoy receptor' for interferon- γ . [33] This inborn error against NTMs can be improved with use of exogenous interferon- γ to boost signalling through the residual receptors on effector cells. [33]

STAT1 GOF variants cause predisposition to chronic fungal infections as well as autoimmunity. [35, 50] *TNFRSF13B* variants increase the risk of autoimmunity and granulomatous inflammation. [51] Knowledge of both these variants in P26 has improved pulmonary and autoimmune monitoring, allowing proactive rather than reactive medicine, and confidence in the need to continue iatrogenic immunosuppression in an immunodeficient individual. Precision medicine is available with the janus kinase inhibitor ruxolitinib for *STAT1* GOF patients. [52]

Biallelic pathogenic *DOCK8* variants cause a combined immunodeficiency that carries a high rate of mortality in early life. [53] As such, knowledge of this variant prompts early referral for bone marrow transplantation which improves outcome. [54, 55]

The participants in whom a monogenic diagnosis was not established are undergoing broader diagnostic investigation such as WES/WGS, and functional interpretation of additional variants identified.

DISCUSSION

This study highlights several advantages and disadvantages of NGS gene panels for diagnostic use in PID. The panel covered a relatively large number of PID genes at high read depth allowing a high sensitivity to detect SNP variants. This is an advantage of gene panels, which have a smaller region of target DNA sequence than WES or WGS. In this study, a ‘virtual’ PID gene panel was applied as a filter to the data generated from the Illumina TruSight One Sequencing Panel (which targets ~12Mb of exonic DNA across 4813 genes in total). This represents a cost effective way of generating sequence data limited to clinically relevant genes. By batching samples we were able to produce results for £180/sample with a turnaround time of 4-8 weeks. In order to achieve this turnaround time close working of a multi-disciplinary team comprising Immunologists, Technologists, Bioinformaticians and Geneticists was required working within the pipeline, and evaluating candidate variants in either a face-to-face or virtual multidisciplinary meetings. The mean read depth over reported PID gene variants in this series was 98 reads, which is more than is typically found in WES or WGS studies. [56] Owing to the smaller region of target DNA sequenced, gene panels generate less data than WES/WGS and therefore are faster to analyse with far fewer variants to interpret than would be expected through an untargeted approach. The risk of incidental/additional genetic findings can also be minimised using a rational, targeted approach to data analysis and interpretation. Together these factors represent a compelling argument for the use of gene panels (albeit as ‘virtual’ panels applied to broader datasets) in the clinical diagnostic investigation of patients. In contrast, research-based analysis, demands wider scale unbiased genomic investigations such as WES/WGS.

In this study the gene panel had an encouraging diagnostic rate at 48% from a genetically undiagnosed phenotypically heterogeneous PID cohort. Knowledge of the monogenic cause for PID had implications for treatments in 37% (10/27) of the cohort, demonstrating the clinical importance of genetic investigation in PID. These data demonstrate that this NGS gene panel approach is efficacious for the investigation of PID patients who are representative of those encountered in clinical practice. As such, this gene panel might reasonably be offered as a first-line genetic investigation for PID patients in the clinic who have a clinical diagnosis of PID as defined by the ESID criteria.

An inherent limitation of gene panels is lack of inclusion of recently described/novel genes. This 242 PID gene panel does not include 67 known PID genes described since its

development (**S3 Table**). Many of these missing genes have subsequently been shown to be prevalent in cohorts of PID patients. [57] Another disadvantage is highlighted by the results of P1, in whom a monogenic diagnosis was not reached with the PID gene panel, but an aCGH identified a large structural variant including the *BACH2* gene as the cause of the patient's condition. [39] Large structural variants are not detectable from NGS gene panels, and although bioinformatics software exists to investigate for structural variants in NGS WES data it remains challenging due to the PCR amplification of DNA during library preparation and need for read de-duplication. This is an advantage of WGS which does not involve PCR amplification of DNA and has contiguous paired-end reads across the genome allowing for the detection of larger structural variants from read depths and split paired-end reads. [58, 59]

In participants P7 and P26, two variants were identified that have been reported to be monogenic causes of PID (**Table 1**). Digenic mechanisms for inherited genetic diseases are well described, but have not been identified in the field of PID. [60] Two distinct monogenic causes for PID have been rarely reported in the same individual resulting in a blended phenotype of 2 underlying monogenic PIDs. [61] Results of large scale genomic investigation studies suggest that approximately 5% of individuals with rare disease, initially considered to have a single monogenic cause for disease, will have a blended phenotype due to the presence of ≥ 2 penetrant monogenic variants. [31] Methods to determine whether in these cases the presence of these two reportable variants represent digenic inheritance models for a single disease entity (that would not manifest without both variants being present) or a blended phenotype due to dual monogenic diagnoses overlapping within the same individual have been developed. [31] Results of our cases show that neither *GATA2:NLRP3* or *STAT1:TNFRSF13B* reside in the same cellular biological pathways (**Fig 2**), suggesting a blend of two monogenic disease phenotypes.

Review of these variants reveals that *NLRP3* p.R490K, initially described as pathogenic causing a periodic fever syndrome, [36] is also reported to show reduced clinical penetrance in some individuals. [62] In P7 the clinical phenotype does contain traits that are supportive of an autoinflammatory syndrome with episodic fever and raised intracranial pressure (**S4 Table**). This clinical information suggests that this variant is at least partially penetrant in this case. P7's clinical phenotype is likely to the result of a pathogenic *GATA2* variant with an additional *NLRP3* variant resulting in a blended phenotype of two distinct monogenic PIDs. Given conflicting literature reports of the pathogenicity of the *NLRP3* p.R490K variant, functional investigation is needed in this individual to clarify the role of this variant.

Identification of *GATA2* haploinsufficiency merits consideration of bone marrow transplant, however at the time of identifying this variant P7's health has deteriorated to condition that bone marrow transplantation was not suitable. Bone marrow transplantation is being increasingly used in adults with PID and knowledge of the monogenic cause for PID is useful in risk stratification for transplantation.

In P26, we consider that these variants may have also resulted in an overlapping blended phenotype as there is no direct interaction or common pathway between *STAT1* and *TNFRSF13B* (**Fig 2**). In P26 the variants *STAT1* p.V266I and *TNFRSF13B* p.Q57H have both been reported to be monogenic pathogenic with supportive functional data within literature. [35, 37] However, another report of *STAT1* p.V277I including a different assessment of phosphorylation studies of *STAT1* p.V266I did not demonstrate any hyperfunctional activity. These conflicting reports mean that one must question whether this truly a pathogenic GOF variant, or a variant displaying incomplete penetrance in some individuals. [63] An additional report of *STAT1* p.V266I in a patient with disseminated mycobacteria is also not typical of the *STAT1* GOF phenotype (although mycobacterial disease is reported in *STAT1* GOF cohorts [50]), but would support the case that this variant impacts on STAT1 protein function *in vivo*. [64] Furthermore, the minor allele frequency of *STAT1* p.V266I (ExAC MAF = 0.002043) is above what may expect given the prevalence of *STAT1* GOF PID. Despite these factors, assessment of the variant against ACMG criteria arrives at the conclusion that it is pathogenic (**Table 1**), demonstrating weight that published literature has on ACMG grading of genetic variants, as well as emphasizing that one must apply a high level of scrutiny to literature and consider clinical phenotype when reviewing genetic variants.

TNFRSF13B variants present a unique challenge in patients with the PID; common variable immunodeficiency (CVID), such as P26. Originally reported to be associated with CVID, [65-67] *TNFRSF13B* variants have been reported as monogenic causes of CVID, with limited additional functional data to support them as a monogenic cause of PID. [68, 69] Large scale studies of the genomics of populations have found that *TNFRSF13B* variants are present at too high a MAF within healthy individuals to be considered monogenic causes of PID. *TNFRSF15B* variants do appear to be genetic risk factors for developing CVID and also convey a increased risk of autoimmunity in patients with CVID. [51] Due to this increased risk of autoimmunity in patients with CVID, knowledge of *TNFRSF13B* variants are important for clinical management of patients, having implications for disease monitoring.

This is reflected in our case, where despite literature reports and the reported low ExAC MAF of the variant, the ACMG classification only grade *TNFRSF13B* p.Q57H as a VUS.

The phenotyping of PID patients often requires detailed, bespoke, functional immunological assays to determine specific defects in cellular functions. [70] This data is difficult to accurately reflect in HPO terms which are often better suited to describe physical characteristics. Often the lack of a specific HPO term for a laboratory assay result (e.g. impairment of specific T cell subset such as Th17 cells) means that a broader term such as ‘impaired T cell function’ (HP:0005435) or ‘abnormality of interleukin secretion’ (HP:0011117) must be substituted. This use of broader HPO terms means that, via semantic relationships used by the *Phenomizer* algorithm, an excessive number of candidate genes are returned which may be missing the correct genetic diagnosis once a $p < 0.05$ to correct for random sampling is applied (**S4 Table**). Due to these current limitations in HPO terminology a broad unbiased approach of interrogating all known PID genes appears to result in a better diagnostic yield than reliance on HPO term driven candidate gene lists. There appears a need to add additional HPO terms and data to improve these results for PID diagnostics in the future.

In conclusion, this study demonstrates the clinical application and benefits that genetic testing has in the clinical care of PID. PID is particularly amenable to precision medicine, and accurate diagnostics readily translate into effective treatments. We demonstrate that this 242 PID gene panel can provide clinically important information for management of PID in the clinic. However, it also highlights some of the limitations and disadvantages of gene panels in the rapidly moving field of PID genomics and the current challenges in accurate HPO term assignment for PID phenotyping.

REFERENCES

1. Bousfiha A, Jeddane L, Al-Herz W et al. The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies. *J Clin Immunol* 2015;35:727-738.
2. Picard C, Al-Herz W, Bousfiha A et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. *J Clin Immunol* 2015;35:696-726.
3. Meyts I, Bosch B, Bolze A et al. Exome and genome sequencing for inborn errors of immunity. *J Allergy Clin Immunol* 2016;138:957-969.
4. Lenardo M, Lo B, Lucas CL. Genomics of Immune Diseases and New Therapies. *Annu Rev Immunol* 2016;34:121-149.
5. Zhang Y, Su HC, Lenardo MJ. Genomics is rapidly advancing precision medicine for immunological disorders. *Nat Immunol* 2015;16:1001-1004.
6. Thrasher AJ, Williams DA. Evolving Gene Therapy in Primary Immunodeficiency. *Mol Ther* 2017;25:1132-1141.
7. Walter JE, Farmer JR, Foldvari Z et al. Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies. *J Allergy Clin Immunol Pract* 2016;4:1089-1100.
8. Fischer A, Provot J, Jais JP et al. Autoimmune and inflammatory manifestations occur frequently in primary immunodeficiencies. *J Allergy Clin Immunol* (in press).
9. Kohn DB, Kuo CY. New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing. *J Allergy Clin Immunol* 2017;139:726-732.
10. Allenspach E, Torgerson TR. Autoimmunity and Primary Immunodeficiency Disorders. *J Clin Immunol* 2016;36:57-67.
11. Bonilla FA, Khan DA, Ballas ZK et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol* 2015;136:1186-1205.

12. Chou J, Ohsumi TK, Geha RS. Use of whole exome and genome sequencing in the identification of genetic causes of primary immunodeficiencies. *Curr Opin Allergy Clin Immunol* 2012;12:623-628.
13. Mousallem T, Urban TJ, McSweeney KM et al. Clinical application of whole-genome sequencing in patients with primary immunodeficiency. *J Allergy Clin Immunol* 2015;136:476-479.
14. Stray-Pedersen A, Sorte HS, Samarakoon P et al. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. *J Allergy Clin Immunol* 2017;138:232-245.
15. Nijman IJ, van Montfrans JM, Hoogstraat M et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. *J Allergy Clin Immunol* 2014;133:529-534.
16. Stoddard JL, Niemela JE, Fleisher TA et al. Targeted NGS: A Cost-Effective Approach to Molecular Diagnosis of PIDs. *Front Immunol* 2014;5:531.
17. Gallo V, Dotta L, Giardino G et al. Diagnostics of Primary Immunodeficiencies through Next-Generation Sequencing. *Front Immunol* 2016;7:466.
18. Al-Mousa H, Abouelhoda M, Monies DM et al. Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases. *J Allergy Clin Immunol* 2016;137:1780-1787.
19. Yu H, Zhang VW, Stray-Pedersen A et al. Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing. *J Allergy Clin Immunol* 2016;138:1142-1151.
20. Köhler S, Vasilevsky NA, Engelstad M et al. The Human Phenotype Ontology in 2017. *Nucleic Acids Res* 2017;45:D865-D876.
21. Köhler S, Schulz MH, Krawitz P et al. Clinical diagnostics in human genetics with semantic similarity searches in ontologies. *Am J Hum Genet* 2009;85:457-464.

22. Erman B, Bilic I, Hirschmugl T et al. Investigation of Genetic Defects in Severe Combined Immunodeficiency Patients from Turkey by Targeted Sequencing. *Scand J Immunol* 2017;85:227-234.
23. Lek M, Karczewski KJ, Minikel EV et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285-291.
24. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. *Nat Methods* 2010;7:248-249.
25. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009;4:1073-1081.
26. Yates A, Akanni W, Amode MR et al. Ensembl 2016. *Nucleic Acids Res* 2016;44:D710-716.
27. Robinson JT, Thorvaldsdóttir H, Winckler W et al. Integrative genomics viewer. *Nat Biotechnol* 2011;29:24-26.
28. Kleinberger J, Maloney KA, Pollin TI et al. An openly available online tool for implementing the ACMG/AMP standards and guidelines for the interpretation of sequence variants. *Genet Med* 2016;18:1165.
29. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405-424.
30. Warde-Farley D, Donaldson SL, Comes O et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res* 2010;38:W214-220.
31. Posey JE, Harel T, Liu P et al. Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation. *N Engl J Med* 2017;376:21-31.
32. Angulo I, Vadas O, Garçon F et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. *Science* 2013;342:866-871.

33. Jouanguy E, Lamhamedi-Cherradi S, Lammas D et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. *Nat Genet* 1999;21:370-378.
34. Côte M, Ménager MM, Burgess A et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. *J Clin Invest* 2009;119:3765-3773.
35. Uzel G, Sampaio EP, Lawrence MG et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. *J Allergy Clin Immunol* 2013;131:1611-1623.
36. Aróstegui JJ, Aldea A, Modesto C et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. *Arthritis Rheum* 2004;50:4045-4050.
37. Almejún MB, Sajaroff E, Galicchio M et al. Immunological characteristics and two novel mutations in TACI in a cohort of 28 pediatric patients with common variable immunodeficiency. *J Clin Immunol* 2012;32:89-97.
38. Cooper GM, Stone EA, Asimenos G et al. Distribution and intensity of constraint in mammalian genomic sequence. *Genome Res* 2005;15:901-913.
39. Afzali B, Grönholm J, Vandrovcova J et al. BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. *Nat Immunol* 2017;18:813-823.
40. Fliegauf M, Bryant VL, Frede N et al. Haploinsufficiency of the NF- κ B1 Subunit p50 in Common Variable Immunodeficiency. *Am J Hum Genet* 2015;97:389-403.
41. Kaustio M, Haapaniemi E, Göös H et al. Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes. *J Allergy Clin Immunol* 2017;140:782-796.
42. Lougaris V, Patrizi O, Baronio M et al. NFKB1 regulates human NK cell maturation and effector functions. *Clin Immunol* 2017;175:99-108.
43. Boztug H, Hirschmugl T, Holter W et al. NF- κ B1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation. *J Clin Immunol* 2016;36:533-540.

44. Schubert D, Bode C, Kenefeck R et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nat Med* 2014;20:1410-1416.
45. Kuehn HS, Ouyang W, Lo B et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. *Science* 2014;345:1623-1627.
46. Lee S, Moon JS, Lee CR et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. *J Allergy Clin Immunol* 2016;137:327-330.
47. Coulter TI, Chandra A, Bacon CM et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. *J Allergy Clin Immunol* 2017;139:597-606.
48. Rae W, Ramakrishnan KA, Gao Y et al. Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome. *Clin Immunol* 2016;171:38-40.
49. Lucas CL, Chandra A, Nejentsev S et al. PI3K δ and primary immunodeficiencies. *Nat Rev Immunol* 2016;16:702-714.
50. Toubiana J, Okada S, Hiller J et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. *Blood* 2016;127:3154-3164.
51. Salzer U, Bacchelli C, Buckridge S et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. *Blood* 2009;113:1967-1976.
52. Weinacht KG, Charbonnier LM, Alroqi F et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. *J Allergy Clin Immunol* 2017;139:1629-1640.
53. Zhang Q, Davis JC, Lamborn IT et al. Combined immunodeficiency associated with DOCK8 mutations. *N Engl J Med* 2009;361:2046-2055.
54. Aydin SE, Kilic SS, Aytekin C et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. *J Clin Immunol* 2015;35:189-198.

55. Al-Herz W, Chu JJ, van der Spek J et al. Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency. *J Allergy Clin Immunol* 2016;138:852-859.
56. Sims D, Sudbery I, Illott NE et al. Sequencing depth and coverage: key considerations in genomic analyses. *Nat Rev Genet* 2014;15:121-132.
57. Bogaert DJ, Dullaers M, Lambrecht BN et al. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? *J Med Genet* 2016;53:575-590.
58. Meienberg J, Bruggmann R, Oexle K et al. Clinical sequencing: is WGS the better WES? *Hum Genet* 2016;135:359-362.
59. Belkadi A, Bolze A, Itan Y et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. *Proc Natl Acad Sci U S A* 2015;112:5473-5478.
60. Schäffer AA. Digenic inheritance in medical genetics. *J Med Genet* 2013;50:641-652.
61. Chinn IK, Sanders RP, Stray-Pedersen A et al. Novel Combined Immune Deficiency and Radiation Sensitivity Blended Phenotype in an Adult with Biallelic Variations in ZAP70 and RNF168. *Front Immunol* 2017;8:576.
62. Haverkamp MH, van de Vosse E, Goldbach-Mansky R et al. Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS). *Clin Exp Immunol* 2014;177:720-731.
63. Depner M, Fuchs S, Raabe J et al. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1. *J Clin Immunol* 2016;36:73-84.
64. Szymanski EP, Leung JM, Fowler CJ et al. Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. *Am J Respir Crit Care Med* 2015;192:618-628.
65. Salzer U, Chapel HM, Webster AD et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. *Nat Genet* 2005;37:820-828.

66. Pan-Hammarström Q, Salzer U, Du L et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. *Nat Genet* 2007;39:429-430.
67. Castigli E, Wilson S, Garibyan L et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. *Nat Genet* 2007;39:430-431.
68. Mohammadi J, Liu C, Aghamohammadi A et al. Novel mutations in TACI (TNFRSF13B) causing common variable immunodeficiency. *J Clin Immunol* 2009;29:777-785.
69. Lougaris V, Gallizzi R, Vitali M et al. A novel compound heterozygous TACI mutation in an autosomal recessive common variable immunodeficiency (CVID) family. *Hum Immunol* 2012;73:836-839.
70. Hsieh EW, Hernandez JD. Novel tools for primary immunodeficiency diagnosis: making a case for deep profiling. *Curr Opin Allergy Clin Immunol* 2016;16:549-556.

LEGENDS

Figure 1

Number of HPO terms assigned across the cohort displayed as a bar graph

Hypogammaglobulinaemia was the most frequently encountered being present in 66% (18/27) participants. There were a number of traits present only in single participants.




Figure 2.

GeneMANIA maps showing the physical interaction (red), biological pathway (blue), and genetic (green) interactions of the 2 genes containing reportable variants from **a.)** P7; *GATA2* and *NLRP3*, and **b.)** P26; *STAT1* and *TNFRSF13B*. Neither *GATA2* and *NLRP3* or *STAT1* and *TNFRSF13B* are directly connected by any biological pathway. These data suggest that these variants cause overlapping phenotypes of 2 discrete diseases, opposed to a digenic mechanism of disease through an additive genetic effect *in vivo*.




Table 1

Reportable genetic results from participants with; Online Mendelian Inheritance in Man (OMIM) database disease number, NGS read depth over variant, in silico results, conservation scores (GERP) [38] and ACMG classification for participants with diagnoses from the PID gene panel. PolyPhen2 scores; 0.0-0.15 benign, 0.15-0.85 possibly damaging, 0.85-1.0 probably damaging. SIFT scores; 0-0.05 damaging, 0.05-1.0 tolerated. [24, 25] VUS = variant of undetermined significance.

Participant	Genetic Result	OMIM Number	Read Depth (Split : Reference/ Alternate)	ExACMAF	PolyPhen2	SIFT	GERP	ACMG classification	Previous report of variant
-------------	----------------	-------------	---	---------	-----------	------	------	---------------------	----------------------------

P2	<i>NFKB1</i> NM_003998 c.904dupT:p.Ser302 Phfs*7	616 576	103 (59/44)	0.00 0116	-	-	5.2 6	Pathogenic (Ia) PVS1, PM6, PP1-S, PM2	Novel
P3	<i>NFKB1</i> NM_003998 c.904dupT:p.Ser302 Phfs*7	616 576	112 (51/61)	0.00 0116	-	-	5.2 6	Pathogenic (Ia) PVS1, PM6, PP1-S, PM2	Novel
P5	<i>IKBKG</i> NM_003639 c.185G>A:p.Arg62Gln hemizygous	300 291	92 (1/91)	<0.0001	0.971	0.01	5.6	Likely pathogenic (IV) PM2, PM5, PM6, PP2, PP3	Novel
P7	<i>GATA2</i> NM_032638.4 c.526A>C:p.Thr176Pro <i>NLRP3</i> NM_004895.4 c.1469G>A:p.Arg490Lys	614 172 606 416	71 (57/14) 161 (84/77)	0 0.00059	0.979 0.992	0.03 0.39	4.01 4.17	Likely pathogenic (IV) PM2, PM6, PP3, PP1-S, PM2 Likely pathogenic (II) PS1, PM6, PP2, PP3, PP5	Novel Arostegui <i>et al.</i> (26)
P10	<i>TAZ</i> NM_181313 c.658A>G:p.Lys220Glu hemizygous	302 060	158 (3/155)	0	0.94	0	5.33	Likely pathogenic (V) PM2, PM6, PP3, PP4	Novel

P16	CTLA4 NM_005214 c.118G>A:p.Val40Met	616 100	118 (60/58)	0	0.595	0.02	5.28	Likely pathogenic (IV) PM2, PM5, PM6, PP2, PP3	Novel
P17	PIK3CD NM_005026 c.3061G>A:p.Glu102Lys	615 513	67 (38/29)	0	0.997	0	3.72	Pathogenic (II) PS1, PS3, PS4, PM1, PM2, PM6	Lucas <i>et al.</i> (28) Angulo <i>et al.</i> (22)
P20	CTLA4 NM_005214 c.160G>A:p.Ala54Thr	616 100	158 (84/74)	0	0.99	0	4.19	Likely pathogenic (II) PM2, PM6, PP2, PP3, PP4	Novel
P23	IFNGR1 NM_00041 c.819_822delTAAT:.. p.Asn274Hisfs*2	615 978	44 (22/22)	0	-	-	2.52	Pathogenic (Ia) PVs1, PS1, PM2, PS3, PP1-M, PM4	Jouanguy <i>et al.</i> (23)
P24	STXBP2 NM_006949 c.1247-1G>C homozygous	613 101	80 (2/78)	0.00 0676	-	-	4.08	Pathogenic (Ia) PVS1, PS1, PS3, PM2, PM3, PP3, PP4	zur Stadt <i>et al.</i> (29)
P25	PIK3CD NM_005026	615 513	71 (38/33)	0	0.982	0	5.35	Likely pathogenic	Rae <i>et</i>

	c.1213C>T:p.Arg405 Cys							(II) PS3, PM2, PP3, PP4	al.(30) (This patient)
P26	STAT1 NM_007315.3 c.796G>A:p.Val266Ile	614 162	74 (44/30)	0.00 419	0.024	0.22	0.791	Pathogenic (II) PS3, PM2, PP3, PP4	Uzel <i>et al.</i> (25)
	TNFSFR13B NM_012452 c.171G>C:p.Gln57His	240 500	63 (27/36)	0.00 090	0.966	0.02	2.19		Almejun <i>et al.</i> (27)
P27	DOCK8 NM_203447.3 c.4792G>T:p.Glu1598* Homozygous	243 700	105 (2/103)	0	-	-	6.17	Pathogenic (Ia) PVS1, PS3, PM2, PM4	Novel

Table 2.

Clinical management alterations/implications resulting from knowledge of the underlying genetic defect in 10/13 genetically diagnosed patients. MMF = mycophenolate mofetil drug.

Participant	Genetic Result	Clinical management/treatment implications	References
P2	NFKB1 NM_003998 c.904dupT:p.Ser302Phefs*7	Autoimmune surveillance, MMF EBV monitoring	Kaustio <i>et al.</i> (35) Boztug <i>et al.</i> (36)
P3	NFKB1 NM_003998 c.904dupT:p.Ser302Phefs*7	Autoimmune surveillance, MMF,	Kaustio <i>et al.</i> (35)

		EBV monitoring	Boztug <i>et al.</i> (36)
P16	<i>CTLA4</i> NM_005214 c.118G>A:p.Val40Met	Abatacept treatment	Lee <i>et al.</i> (37) Schubert <i>et al.</i> (38)
P17	<i>PIK3CD</i> NM_005026 c.3061G>A:p.Glu1021Lys	Sirolimus, Idelalisib treatments	Lucas <i>et al.</i> (28) Lucas <i>et al.</i> (39) Rae <i>et al.</i> (40)
P20	<i>CTLA4</i> NM_005214 c.160G>A:p.Ala54Thr	Abatacept treatment	Lee <i>et al.</i> (37) Schubert <i>et al.</i> (38)
P23	<i>IFNGRI</i> NM_00041 c.819_822delTAAT:p.Asn274Hisfs*2	Adjuvant interferon-gamma	Jouanguy <i>et al.</i> (23) Wu <i>et al.</i> (41)
P24	<i>STXBP2</i> NM_006949 c.1247-1G>C homozygous	Herpes virus monitoring, aciclovir prophylaxis	zur Stadt <i>et al.</i> (29) Esmailzadeh <i>et al.</i> (42) Maffuci <i>et al.</i> (43)
P25	<i>PIK3CD</i> NM_005026 c.1213C>T:p.Arg405Cys	Sirolimus, Idelalisib treatments	Lucas <i>et al.</i> (28) Lucas <i>et al.</i> (39) Rae <i>et al.</i> (40)
P26	<i>STAT1</i> NM_007315.3 c.796G>A:p.Val266Ile <i>TNFSFR13B</i> NM_012452 c.171G>C:p.Gln57His	Autoimmune surveillance, MMF, ruxolitinib.	Weinacht <i>et al.</i> (44) Toubiana <i>et al.</i> (45) Salzer <i>et al.</i> (46)
P27	<i>DOCK8</i> NM_203447.3 c.4792G>T:p.Glu1598* Homozygous	Bone marrow transplant	Aydin <i>et al.</i> (47) Al-Herz <i>et al.</i> (48)